The Latest Analyst Ratings For 4D Molecular Therapeutics
The Latest Analyst Ratings For 4D Molecular Therapeutics
4d分析師評級的最新消息
4D Molecular Therapeutics (NASDAQ:FDMT) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
4D Molecular Therapeutics（納斯達克股票代碼：FDMT）在上個季度接受了5位分析師的分析，揭示了從看漲到看跌的一系列觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $38.8, with a high estimate of $40.00 and a low estimate of $36.00. This current average represents a 10.6% decrease from the previous average price target of $43.40.
分析師對12個月目標股價的評估提供了更多見解，顯示平均目標價爲38.8美元，最高估計爲40.00美元，低估值爲36.00美元。目前的平均價格比之前的平均目標價43.40美元下降了10.6％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
A clear picture of 4D Molecular Therapeutics's perception among financial...
通過對分析師近期行爲...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。